HIV and AIDS Trial, Recruiting NCT06406049 Sponsor: University of Miami Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT06406049
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 18 and 54 years old
  • People who are cisgender men (born male and identify as male)
  • People who identify as Latinx
  • People who report being HIV negative
  • People who are willing to be tested for HIV
  • People who are willing to follow all study procedures and take part for the full duration of the study
  • People who have signed and dated a consent form agreeing to take part
  • People who, in the last 6 months, have had at least one of the following: been diagnosed with a bacterial sexually transmitted infection (such as syphilis, gonorrhea, or chlamydia); had sex with a partner living with HIV; had sex without a condom with two or more partners whose HIV status was unknown; or injected drugs and shared injection equipment

Who may not be able to join:

  • People who are younger than 18 or older than 54 years of age
  • People who report living with HIV
  • People who test positive for HIV during the study screening process (applies to certain participant groups — confirm with trial site)
  • People who refuse to take an HIV test
  • People who do not identify as Latinx
  • People who are currently enrolled in another program aimed at starting PrEP (HIV prevention medication)
  • People who have had an active PrEP prescription (either pill or injection form) at any point in the last 6 months
  • People who are unable to give informed consent due to cognitive impairment or severe psychiatric symptoms, such as mania or psychosis, as assessed by trained study interviewers

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mariano Kanamori, PhD, University of Miami

Phone: (305) 2430595

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 November 2024
Est. completion
31 May 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants that report using PrEP; Number of Dried Blood Spot (DBS) tests that report PrEP use; Number of participants that bring a proof of PrEP prescription

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov